要批了！# Stock
P*B
1 楼
The FDA has further informed us that data from short-term endpoints
measuring symptomatic benefits may be sufficient evidence of efficacy as
required for approval and that durability of response, determined by
endpoints measuring long-term symptomatic benefits, may be studied and
demonstrated in post-approval study or studies
measuring symptomatic benefits may be sufficient evidence of efficacy as
required for approval and that durability of response, determined by
endpoints measuring long-term symptomatic benefits, may be studied and
demonstrated in post-approval study or studies
